Upstream Bio
Upstream Bio62
About
What does Upstream Bio do?
Upstream Bio is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory diseases. Their lead program is a monoclonal antibody designed to inhibit the TSLP receptor, a key upstream mediator in multiple inflammatory signaling pathways. By targeting TSLP, Upstream Bio aims to address a broad range of immune-mediated conditions.
What is Upstream Bio's revenue?
StartupHub estimates Upstream Bio's annual revenue at $13.5M (range $7.1M to $20.7M, 64% confidence), based on comparable companies in the sector.
What is Upstream Bio's valuation?
StartupHub estimates Upstream Bio's effective valuation at $1.7B (range $1.0B to $2.4B, 10% confidence), based on comparable companies in the sector.
How much funding has Upstream Bio raised?
Upstream Bio has raised a total of $400M in funding. The most recent round on record is Series B.
Where is Upstream Bio headquartered?
Upstream Bio is headquartered in Waltham, United States.
When was Upstream Bio founded?
Upstream Bio was founded in 2021.
What industry does Upstream Bio operate in?
Upstream Bio operates in Life Sciences, Therapeutics, Biotech, Drug Discovery, Clinical Trials, HealthTech.
How many employees does Upstream Bio have?
Upstream Bio has approximately 75 people on record.
No comments yet. Be the first to share your take.